

# Call for Abstracts

North American Veterinary Dermatology Forum  
April 27-30, 2025  
Orlando, Florida

The program committee of the 2025 North American Veterinary Dermatology Forum (NAVDF) is calling for contributions for Free Communications (Original Research, Clinical, Resident, and Poster abstract sessions) to be presented at next year's meeting in Orlando, Florida.

**Original Research Abstracts:** This session will consist of short oral presentations (12 minutes) of original scientific studies (basic, applied, clinical) in animal or comparative dermatology.

**Clinical Abstracts:** This session will consist of short oral presentations (10-12 minutes) of interesting case reports or clinical studies.

**Resident Abstracts:** This session will consist of short oral presentations (12 minutes) of the ACVD residents' original research.

**Posters:** This session will consist of reports in poster format of investigative and clinical studies. The size of the poster boards will be 4' x 4'. Poster abstracts should be no larger than 4 feet by 4 feet (4' x 4'). The posters will be available for viewing from Sunday through Wednesday.

Studies submitted should not have been presented at a national or international meeting nor published prior to the 2025 NAVDF. Abstract authors are expected to register for NAVDF. Abstracts submitted for all sessions should **adhere strictly** to the format guidelines for the NAVDF (see attached guidelines and example abstract). The abstracts must include the final results of the study. Incomplete abstracts or failure to follow the format will lead to rejections of the paper without review. Each abstract will be evaluated blindly by three to five members of the program committee and scored based on design, originality, and relevance to veterinary dermatology. The abstracts will be ranked according to score and selected for presentation in the session requested or deemed appropriate, based on available space. For 2025, all presentations (except posters) are required to be prepared utilizing Power Point and copied to a flash drive for LCD projection.

Please refer to the accompanying Author's Instructions, Format for Abstracts, Abstract Submission form; and sample abstract for additional information.

# Authors Instructions

North American Veterinary Dermatology Forum  
Free Communications (Research, Clinical, Resident & Poster Abstracts)

Please read ALL instructions.

1. **Deadline:** The deadline for reception of all abstracts is **November 1, 2024**. **Material must be received in the proper format by 11:59pm Pacific Daylight Time. There will be no extensions for this deadline. For registered ACVD residents only, the submission deadline is December 1, 2024, 11:59pm Pacific Standard Time.**
2. **Submissions:** Abstracts should be submitted online through a link which will be provided in the future.

<https://venuewest.eventsair.com/PresentationPortal/Account/Login?ReturnUrl=%2FPresentationPortal%2Fnavdf2025%2Fabstract-submission>

3. **Conflicts of interest:** In accordance with ethical guidelines pertaining to scientific meetings, a notation will be made in the Abstracts Section of the Proceedings if there are any abstracts to be presented by authors who may have a conflict of interest. A conflict of interest includes, but is not limited to, any significant financial interest in a company, product, or procedure that is mentioned in an abstract or presentation to be given at the meeting. If the author or presenter feels that such a conflict exists, the box provided on the Abstract Submission Form should be checked, so that the conflict of interest may be noted in the Supplement. Checking this box in no way affects whether an abstract is accepted for presentation. Any conflicts of interest should be included in the abstract (see sample abstract). In addition, we ask that speakers take a moment at the beginning of their presentations to disclose any personal financial self-interest or gain, profit or royalty relationship to the audience, via a PowerPoint slide. Authors of posters are asked to disclose any personal financial self-interest or gain, profit or royalty relationship as part of their poster presentation.

Abstract Submission Form (2 pages)

**North American Veterinary Dermatology Forum  
April 27-30, 2025**

**Submission Deadline: November 1, 2024 (11:59pm PST/PDT)**

***Resident Submission Deadline (only for registered ACVD residents!):  
December 1, 2024\* (11:59pm PST/PDT)***

1. **Title of abstract:**

2. **Name and address of corresponding author:**

Name:

Mailing address:

Telephone number:

Email:

3. **Submission Category**

Please indicate your preference by number: 1 = most preferred, 3 = least preferred; 0 = not acceptable

Original Research

Clinical Abstract

Poster Session

Resident Abstract

4.  Check this box if there is a possible **conflict of interest** in presenting this information on the part of the author(s) or presenter. See conflict of interest information in Author Instructions.

<p>Abstract Submission Form (Page 2)</p> <p><b>North American Veterinary Dermatology Forum</b> <b>April 27-30, 2025</b> <b>Submission Deadline: November 1, 2024 (11:59pm PST/PDT)</b></p> <p><b><i>Resident Submission Deadline (only for registered ACVD residents!):</i></b> <b><i>December 1, 2024* (11:59pm PST/PDT)</i></b></p>
---

5. By agreeing to present, Speaker grants to NAVDF Program the following rights to any written or visual material submitted in connection with your presentation(s) at the Program in any and all media or form of communication whether now existing or hereafter developed: (1) the non-exclusive worldwide right to transcribe, publish, reproduce, distribute, sell, display, or license your presentation(s), as presented in the Program, alone or in conjunction with other materials; (2) the non-exclusive worldwide right to use your presentation(s) as part of a course book or in any other publication produced by NAVDF; (3) the non-exclusive worldwide right to use your presentation to promote and publicize NAVDF; and (4) the non-exclusive right to use your name, likeness and biography in connection with the advertising, publicity, and promotion of your presentation(s) and/or NAVDF.

6. It is the responsibility of the abstract author to contact Alexis Borich via email ([Executive\\_Sec@acvd.org](mailto:Executive_Sec@acvd.org)) if you have not been notified of the status of your abstract by January 10, 2025. Abstract selection will be finalized by January 24, 2025.

You warrant that you have full power and authority to enter into this Agreement, and that your presentation(s) and any other material you submit (1) are original with you; (2) are not subject to any third party copyright or that you have obtained permission from the copyright proprietor consistent with this Agreement for use of any third party copyrighted material; and (3) that publication will not libel anyone or infringe on or invade the rights of others. You agree that you will provide any applicable permission agreements for the use of third party copyrighted material upon request and indemnify NAVDF for any liability or costs incurred by breach of this warranty

**I certify that the material submitted is original and has not been published or presented elsewhere.**

Author's Signature: \_\_\_\_\_

Printed Name: \_\_\_\_\_

Date: \_\_\_\_\_

**Format for Abstracts – ALL SESSIONS**  
**North American Veterinary Dermatology Forum**

Abstracts should be formatted as follows:

1. Length: 250 words maximum excluding title, authors, source of funding and conflict of interest.
2. Font: 12 pt Arial or Verdana or other Sans Serif font only, single space, 1 inch margins
3. One paragraph. No tables, graphs or references should be included in the abstract
4. Heading – should be aligned to the left, each part starting on a new line:
  - i. Title: bold, no capital letters except for first word and proper names.
  - ii. Authors: not bold: Initials and last name only, use capitals, no degrees / qualifications / titles are required.
  - iii. Affiliations: use *italics*, not bold: Name of department, University / Institution / Company, City, State, Country: Do not include full postal addresses. Native language versions are acceptable (e.g. München Universität). No postcode is required.
  - iv. Use symbols (not superscripts) to indicate author affiliation as in the following example: (*Where there is only one institution then there is no need for any symbols*)

HEADING EXAMPLE

**Quality of life for dogs with dermatological disease**

C. SMITH\*, S. SMITH†, L. SMITH‡, G. R. T. SMITH§, P. SMITH¶ and A. SMITH\*\*

\**Pets Veterinario, Borgo Sangimino (CN), Italy*

†*The University of Edinburgh, Roslin, UK*

‡*College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA*

§*Laboratory of Veterinary Internal Medicine, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, Japan*

¶*Animal Dermatology Clinic, Los Angeles, CA, USA*

\*\**Institute for Human Genetics, Freiburg, Germany*

5. Text - justified and single space. All pages must be in the 8.5 inch x 11 inch format. Abstract should be **one** paragraph.

**6. General advice on format**

- i. Start abstract with “**Abstract:**” See example below.
- ii. Where products are mentioned, include the manufacturer’s name and address e.g. ciclosporin (Atopica, Novartis Animal Health; Greensboro, NC, USA). Where multiple products are mentioned there will be flexibility employed to keep the abstract to ≤250 words and to just use product and manufacturer names.

- iii. Drug doses should be given as: mg/kg, µg/kg; also include once or twice daily and route of administration.
- iv. Laboratory data is reported in IU units.
- v. Breed names are adjectives not nouns, so it is Siamese cat, not “Siamese” or Labrador retriever, not Labrador.
- vi. Breed names are capitalized only if they are proper names, e.g. German shepherd dog not German Shepherd Dog, mixed breed dog not Mixed Breed Dog. Animal breed names are usually not capitalized unless derived from the name of a place (e.g. Weimeraner).
- vii. It is acceptable to summarize data as follows, to conserve text: 3/9 dogs.
- viii. Use the following abbreviations: h for hours, min for min, sec for seconds.
- ix. Units of measurement should be given as (e.g.) 16.5 g/m<sup>2</sup>/h (e.g. is for TEWL).
- x. Drug names are based on the rINN system – e.g. please use cefalexin, meticillin, ciclosporin.
- xi. *P* values should be given as  $p=0.005$  or  $\leq 0.05$ ; down to 0.0001; use up to two numbers: 0.0055 or 0.0058. Note lower case *p* is in italics and no spacing between “*p*” and “=” and “0.005”, e.g.  $p\leq 0.05$ .
- xii. Units of measurement: SI or SI-derived units (<https://www.bipm.org/en/about-us/> for more information). ‘L’ for litre, not ‘l’.
- xiii. Numbers should always be spelled out in the beginning of a sentence. Numbers: spell out numbers up to nine (under 10) in full, this includes days, weeks, months and years, but not minutes or seconds. Age is the exception to the “numbers under 10 spelled out” rule. For lists with other numbers write as follows: 11 dogs, nine cats, four gerbils. But not for: measurements with a unit (8 mmol/L). Use ‘four of five’ or ‘4/5’ and not ‘four out of five’. Ratios: 1:10,000 (no space around the colon). Age should be written as: 2-year-old or 10-year-old; with “Two-year-old” at the start of a sentence.
- xiv. ‘Adverse effects’, NOT ‘side-effects’.
- xv. T cells (no hyphen), but T-cell response (hyphenate if used adjectivally).
- xvi. ‘short-haired’ NOT shorthaired.
- xvii. Chemical substances and drugs should be referred to by the generic name only. If proprietary drugs have been used in the study, refer to these by their generic name at first use, mentioning the proprietary name and the name and location (city, (state), country) of the manufacturer in parentheses, e.g. fenbendazole (Panacur, Intervet-Schering Plough; Milton Keynes, UK). Spellings of drugs should follow the recommended International Non-Proprietary Names (rINN).

Common examples include cefalexin, ciclosporin, meticillin and rifampicin. Abbreviations for drug administration; after first use, always abbreviate i.d. (intradermal), i.m. (intramuscular), i.p. (intraperitoneal), i.v. (intravenous), p.o. (per os, oral), p.r. (per rectum, rectal), s.c. (subcutaneous) and s.l. (sublingual). For example use per os first then thereafter use p.o.

- xviii. Products such as equipment, software or methods: Product name (Company name; town or city, (state) and country); e.g. Datex CD 200-02 (Datex; Hatfield, UK); or SuperScript<sup>®</sup> III First-Strand Synthesis kit (Invitrogen; Carlsbad, CA, USA).
- xix. Microbes: Taxonomic names in italics, e.g. *Staphylococcus pseudintermedius* (at subsequent mentioning: *S. pseudintermedius*) but non-systematic names (e.g. plural) lower case and not italicised, e.g. staphylococci.
- xx. For genes, proteins please refer to recent articles in *Veterinary Dermatology*.
- xxi. Abbreviations: keep to a minimum, only use if the term is needed repeatedly; need to be written in full at first use.

7. **Conflicts of interest** should be given as “**Conflict of interest:** None declared.” The Conflict of interest is in **bold** and the conflicts not bolded with a period at the end (no italics). It is the author’s responsibility to state any conflicts.

8. Similarly for “**Source of funding:** Self-funded.” at the end of the abstract, With the Source of funding in **bold** and the source not bolded with a period at the end, separated from the main body of abstract by one space line (no italics). Do not use acronyms for funding bodies – please write out the full title of each funding body.

